|
FR2535721A1
(fr)
|
1982-11-08 |
1984-05-11 |
Sanofi Sa |
Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives
|
|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
|
FR2588189B1
(fr)
|
1985-10-03 |
1988-12-02 |
Merck Sharp & Dohme |
Composition pharmaceutique de type a transition de phase liquide-gel
|
|
JP2518353B2
(ja)
|
1988-06-09 |
1996-07-24 |
住友化学工業株式会社 |
シアノ酢酸アミド誘導体およびその製造中間体
|
|
CA2018801C
(en)
|
1990-06-12 |
2000-08-22 |
Pierre Louis Beaulieu |
Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
|
|
JPH04177244A
(ja)
|
1990-11-10 |
1992-06-24 |
Konica Corp |
ハロゲン化銀写真感光材料
|
|
CA2033447C
(en)
|
1990-12-31 |
1999-08-31 |
Robert Deziel |
Synergistic combination for treating herpes infections
|
|
ATE141502T1
(de)
|
1991-01-15 |
1996-09-15 |
Alcon Lab Inc |
Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
|
|
US5212162A
(en)
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
|
JPH05301838A
(ja)
|
1991-10-15 |
1993-11-16 |
Mitsubishi Kasei Corp |
スチレン誘導体
|
|
US5792771A
(en)
|
1992-11-13 |
1998-08-11 |
Sugen, Inc. |
Quinazoline compounds and compositions thereof for the treatment of disease
|
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
|
JPH0827090A
(ja)
|
1994-05-13 |
1996-01-30 |
Sumitomo Chem Co Ltd |
シアノ酢酸アミド誘導体、その用途およびその製造中間体
|
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
IL131581A
(en)
|
1997-03-14 |
2003-12-10 |
Basf Ag |
Cycloalkylalkanecarboxamides, their production and fungicide compositions comprising them
|
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
|
IL125947A0
(en)
|
1997-09-17 |
1999-04-11 |
American Cyanamid Co |
3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents
|
|
DE69814122T2
(de)
|
1997-10-09 |
2004-03-18 |
Dexcel Pharma Technologies Ltd. |
Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
|
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
|
PL215901B1
(pl)
|
1999-04-15 |
2014-02-28 |
Bristol Myers Squibb Co |
Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
|
|
CA2385747A1
(en)
|
1999-09-17 |
2001-03-22 |
Gavin C. Hirst |
Pyrazolopyrimidines as therapeutic agents
|
|
WO2001072751A1
(en)
|
2000-03-29 |
2001-10-04 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines as tyrosine kinase inhibitors
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
|
WO2003037890A2
(en)
|
2001-11-01 |
2003-05-08 |
Icagen, Inc. |
Piperidines
|
|
JP3991812B2
(ja)
|
2001-12-11 |
2007-10-17 |
住友化学株式会社 |
エステル化合物およびその用途
|
|
WO2003068157A2
(en)
|
2002-02-11 |
2003-08-21 |
The Brigham And Women's Hospital, Inc. |
Kinase inhibitors and methods of use thereof
|
|
NI200300043A
(es)
|
2002-03-28 |
2003-11-05 |
Warner Lambert Co |
AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
|
|
FR2842735B1
(fr)
|
2002-07-26 |
2006-01-06 |
Flamel Tech Sa |
Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
|
|
GB0219024D0
(en)
|
2002-08-15 |
2002-09-25 |
Pfizer Ltd |
Synergistic combinations
|
|
US7419981B2
(en)
|
2002-08-15 |
2008-09-02 |
Pfizer Inc. |
Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
|
|
GB0226370D0
(en)
|
2002-11-12 |
2002-12-18 |
Novartis Ag |
Organic compounds
|
|
JP2006518368A
(ja)
|
2003-02-21 |
2006-08-10 |
ファイザー・インク |
プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
|
|
WO2004100868A2
(en)
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
|
US7285562B2
(en)
|
2003-08-01 |
2007-10-23 |
Chugai Seiyaku Kabushiki Kaisha |
Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors
|
|
KR20090080143A
(ko)
|
2003-09-02 |
2009-07-23 |
화이자 프로덕츠 인크. |
지프라시돈의 지속 방출형 투여 형태
|
|
WO2005023773A1
(en)
|
2003-09-04 |
2005-03-17 |
Pfizer Limited |
Process for the preparation of substituted aryl pyrazoles
|
|
GB0322140D0
(en)
|
2003-09-22 |
2003-10-22 |
Pfizer Ltd |
Combinations
|
|
BRPI0414798A
(pt)
|
2003-09-25 |
2006-11-21 |
Warner Lambert Co |
métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
|
|
JP2007520559A
(ja)
|
2004-02-03 |
2007-07-26 |
アボット・ラボラトリーズ |
治療薬としてのアミノベンゾオキサゾール類
|
|
JP4552456B2
(ja)
|
2004-02-27 |
2010-09-29 |
住友化学株式会社 |
エステル化合物およびその用途
|
|
WO2005085210A1
(ja)
|
2004-03-10 |
2005-09-15 |
Ono Pharmaceutical Co., Ltd. |
ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
|
|
US7807719B2
(en)
|
2004-09-14 |
2010-10-05 |
Chaim Roifman |
Compounds useful for modulating abnormal cell proliferation
|
|
WO2006036941A2
(en)
|
2004-09-27 |
2006-04-06 |
Kosan Biosciences Incorporated |
Specific kinase inhibitors
|
|
CA2597587A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
|
EP1863449A2
(en)
|
2005-03-28 |
2007-12-12 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
|
AU2006343359A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
|
DE602006012042D1
(de)
|
2005-06-15 |
2010-03-18 |
Pfizer Ltd |
Substituierte arylpyrazole zur verwendung gegen parasiten
|
|
US20070149464A1
(en)
|
2005-06-15 |
2007-06-28 |
Pfizer Inc. |
Combination
|
|
US20080146643A1
(en)
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
|
US20080176865A1
(en)
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
|
GB0517205D0
(en)
|
2005-08-22 |
2005-09-28 |
Novartis Ag |
Organic compounds
|
|
KR20080066938A
(ko)
|
2005-10-07 |
2008-07-17 |
깃세이 야쿠힌 고교 가부시키가이샤 |
질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
|
|
ES2432361T3
(es)
|
2005-12-02 |
2013-12-03 |
Bayer Healthcare, Llc |
Derivados de pirrolotriazina útiles para el tratamiento de cáncer por inhibición de cinasa Aurora
|
|
KR20080098490A
(ko)
|
2006-01-13 |
2008-11-10 |
파마시클릭스, 인코포레이티드 |
티로신 키나제 억제제 및 이의 용도
|
|
BRPI0709916B8
(pt)
|
2006-03-31 |
2021-05-25 |
Univ Texas |
drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
|
|
US7645748B2
(en)
|
2006-04-03 |
2010-01-12 |
Forbes Medi-Tech Inc. |
Sterol/stanol phosphorylnitroderivatives and use thereof
|
|
EP2029597A4
(en)
|
2006-05-31 |
2011-11-23 |
Univ California |
purine analogs
|
|
WO2008005954A2
(en)
|
2006-06-30 |
2008-01-10 |
The Board Of Regents Of The University Of Texas System |
Tryphostin-analogs for the treatment of cell proliferative diseases
|
|
EP2049500B1
(en)
|
2006-07-06 |
2011-09-07 |
Array Biopharma, Inc. |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
JP2010519178A
(ja)
|
2006-11-23 |
2010-06-03 |
ノバルティス アーゲー |
ピリミジン類およびｃｘｃｒ２受容体アンタゴニストとしてのその使用
|
|
EP2125819B1
(en)
|
2007-03-21 |
2014-10-22 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
|
|
GB2447933A
(en)
|
2007-03-27 |
2008-10-01 |
Chemence Ltd |
Cyanoacrylate monomer for forming an adhesive polymer
|
|
IL295053A
(en)
|
2007-03-28 |
2022-09-01 |
Pharmacyclics Llc |
Broton tyrosine kinase inhibitors
|
|
JP5368485B2
(ja)
|
2008-02-25 |
2013-12-18 |
エフ．ホフマン−ラ ロシュ アーゲー |
ピロロピラジンキナーゼインヒビター
|
|
ATE522536T1
(de)
|
2008-02-25 |
2011-09-15 |
Hoffmann La Roche |
Pyrrolopyrazin-kinasehemmer
|
|
WO2009140128A2
(en)
|
2008-05-13 |
2009-11-19 |
Irm Llc |
Compounds and compositions as kinase inhibitors
|
|
EP2310389B1
(en)
|
2008-05-22 |
2012-01-04 |
Amgen Inc. |
Heterocycles as protein kinase inhibitors
|
|
ES2660418T3
(es)
|
2008-07-16 |
2018-03-22 |
Pharmacyclics Llc |
Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
|
|
US20110165183A1
(en)
|
2008-08-01 |
2011-07-07 |
Biocryst Pharmaceuticals, Inc. |
Piperidine derivatives as jak3 inhibitors
|
|
US8450337B2
(en)
|
2008-09-30 |
2013-05-28 |
Moleculin, Llc |
Methods of treating skin disorders with caffeic acid analogs
|
|
US20120028981A1
(en)
|
2008-11-05 |
2012-02-02 |
Principia Biopharma Inc. |
Kinase Knockdown Via Electrophilically Enhanced Inhibitors
|
|
US20100113520A1
(en)
|
2008-11-05 |
2010-05-06 |
Principia Biopharma, Inc. |
Kinase knockdown via electrophilically enhanced inhibitors
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
EP2475375A4
(en)
|
2009-09-09 |
2013-02-20 |
Avila Therapeutics Inc |
PI3 KINASE INHIBITORS AND USES THEREOF
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
CA2781056A1
(en)
|
2009-11-16 |
2011-05-19 |
Rebecca Maglathlin |
Kinase inhibitors
|
|
CA2799904A1
(en)
|
2010-05-20 |
2011-11-24 |
F. Hoffmann-La Roche Ag |
Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
|
|
BR112012030711B1
(pt)
|
2010-05-31 |
2020-10-13 |
Ono Pharmaceutical Co. Ltd |
derivado de purinona
|
|
US20120071497A1
(en)
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
|
CN107898791A
(zh)
|
2010-06-03 |
2018-04-13 |
药品循环有限责任公司 |
布鲁顿酪氨酸激酶(btk)抑制剂的应用
|
|
CN101880243A
(zh)
|
2010-06-04 |
2010-11-10 |
贵阳柏丝特化工有限公司 |
一种含氟氰拟除虫菊酯化合物及其合成方法与用途
|
|
CN105566229A
(zh)
|
2010-08-10 |
2016-05-11 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐及其用途和制备方法
|
|
MX382354B
(es)
|
2010-11-01 |
2025-03-13 |
Celgene Car Llc |
Compuestos heterocíclicos y usos de los mismos.
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
EA025496B1
(ru)
|
2011-05-17 |
2016-12-30 |
Принсипиа Биофарма Инк. |
Ингибиторы тирозинкиназы
|
|
US20140107151A1
(en)
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
|
CA2836449C
(en)
|
2011-05-17 |
2021-04-27 |
The Regents Of The University Of California |
Kinase inhibitors
|
|
US8828426B2
(en)
|
2011-06-07 |
2014-09-09 |
Zx Pharma, Llc |
Multiparticulate L-carnitine compositions and related methods
|
|
CA2840413A1
(en)
|
2011-06-28 |
2013-01-03 |
Pharmacyclics, Inc. |
Methods and compositions for inhibition of bone resorption
|
|
US9138436B2
(en)
|
2011-07-13 |
2015-09-22 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
BR112014001255B1
(pt)
|
2011-07-19 |
2019-07-02 |
Merck Sharp & Dohme B.V. |
Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
|
|
JP2014522860A
(ja)
|
2011-07-19 |
2014-09-08 |
メルク・シャープ・アンド・ドーム・ベー・フェー |
Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
|
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
|
WO2013041605A1
(en)
|
2011-09-20 |
2013-03-28 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
|
|
WO2013059738A2
(en)
|
2011-10-19 |
2013-04-25 |
Pharmacyclics, Inc. |
Use of inhibitors of bruton's tyrosine kinase (btk)
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
|
JO3754B1
(ar)
|
2012-06-04 |
2021-01-31 |
Pharmacyclics Llc |
أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
|
|
US9353087B2
(en)
|
2012-06-08 |
2016-05-31 |
Biogen Ma Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
CN104487441B
(zh)
|
2012-06-18 |
2018-06-01 |
普林斯匹亚生物制药公司 |
有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
|
|
WO2014004707A1
(en)
|
2012-06-29 |
2014-01-03 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
|
US20150209432A1
(en)
|
2012-07-26 |
2015-07-30 |
Lupin Limited |
Pharmaceutical compositions of proton pump inhibitor
|
|
WO2014022569A1
(en)
|
2012-08-03 |
2014-02-06 |
Principia Biopharma Inc. |
Treatment of dry eye
|
|
ME03455B
(me)
|
2012-09-10 |
2020-01-20 |
Principia Biopharma Inc |
Jedinjenja pirazolopirimidina kao inhibitori kinaze
|
|
JP6178861B2
(ja)
|
2012-11-02 |
2017-08-09 |
ファイザー・インク |
ブルトン型チロシンキナーゼ阻害剤
|
|
SG11201503459SA
(en)
|
2012-11-02 |
2015-06-29 |
Pharmacyclics Inc |
Tec family kinase inhibitor adjuvant therapy
|
|
EA201590855A1
(ru)
|
2012-11-15 |
2015-11-30 |
Фармасайкликс, Инк. |
Соединения пирролопиримидина как ингибиторы киназ
|
|
US20140142099A1
(en)
|
2012-11-20 |
2014-05-22 |
Principia Biopharma Inc. |
Purinone Derivatives as Tyrosine Kinase Inhibitors
|
|
KR20150099588A
(ko)
|
2012-12-20 |
2015-08-31 |
더 펜 스테이트 리서어치 파운데이션 |
암의 치료와 관련된 방법 및 조성물
|
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
WO2014171542A1
(ja)
|
2013-04-19 |
2014-10-23 |
武田薬品工業株式会社 |
放出制御製剤
|
|
MX2016009403A
(es)
|
2014-02-03 |
2016-09-16 |
Cadila Healthcare Ltd |
Compuestos heterociclicos.
|
|
KR20160124157A
(ko)
*
|
2014-02-20 |
2016-10-26 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
|
|
PT3107544T
(pt)
|
2014-02-21 |
2021-01-05 |
Principia Biopharma Inc |
Sais e forma sólida de um inibidor de btk
|
|
US10485797B2
(en)
|
2014-12-18 |
2019-11-26 |
Principia Biopharma Inc. |
Treatment of pemphigus
|
|
DK3236943T3
(da)
|
2014-12-24 |
2023-04-11 |
Principia Biopharma Inc |
Sammensætninger til ileo-jejunal lægemiddeladministration
|
|
CA2971109C
(en)
|
2014-12-24 |
2024-07-02 |
Principia Biopharma Inc. |
SITE-SPECIFIC DOSAGE OF A BTK INHIBITOR
|
|
UA124090C2
(uk)
|
2015-06-03 |
2021-07-21 |
Прінсіпіа Байофарма Інк. |
Інгібітори тирозинкінази
|
|
TW201718572A
(zh)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
酪胺酸激酶抑制劑
|
|
CN105753863B
(zh)
|
2015-09-11 |
2018-07-31 |
东莞市真兴贝特医药技术有限公司 |
氧代二氢咪唑并吡啶类化合物及其应用
|
|
EP3414234B1
(en)
|
2015-10-14 |
2022-06-29 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
MA45547A
(fr)
|
2016-06-29 |
2019-05-08 |
Principia Biopharma Inc |
Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
|
|
WO2019208805A1
(ja)
|
2018-04-27 |
2019-10-31 |
小野薬品工業株式会社 |
Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
|
|
CN110483521B
(zh)
|
2018-05-14 |
2022-06-07 |
杭州和正医药有限公司 |
一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用
|
|
TWI877239B
(zh)
|
2019-10-14 |
2025-03-21 |
美商普林斯匹亞生物製藥公司 |
藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
|
|
JP2023511105A
(ja)
|
2020-01-22 |
2023-03-16 |
プリンシピア バイオファーマ インコーポレイテッド |
２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態
|
|
WO2022081512A1
(en)
|
2020-10-12 |
2022-04-21 |
Synubi Pharmaceuticals Llc |
Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
|